AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
10 Feb 2014 05:30 PM
RNS
Director/PDMR Shareholding
07 Feb 2014 03:30 PM
RNS
Director/PDMR Shareholding
06 Feb 2014 07:00 AM
RNS
Pipeline Table
06 Feb 2014 07:00 AM
RNS
Final Results
05 Feb 2014 09:00 AM
RNS
Notice of Results
03 Feb 2014 04:30 PM
RNS
Total Voting Rights
03 Feb 2014 07:00 AM
RNS
AZ completes BMS diabetes acquisition
27 Jan 2014 10:30 AM
RNS
Holding(s) in Company
22 Jan 2014 07:00 AM
RNS
Xigduo approved in EU for type 2 diabetes
17 Jan 2014 10:42 AM
RNS
Replacement re block listing application
17 Jan 2014 07:00 AM
RNS
Block Listing Application
14 Jan 2014 07:00 AM
RNS
AstraZeneca provides strategy update at JP Morgan
13 Jan 2014 07:00 AM
RNS
US FDA APPROVES FARXIGAT (DAPAGLIFLOZIN)
09 Jan 2014 07:00 AM
RNS
US FDA Approval of Farxiga (dapagliflozin)
02 Jan 2014 04:00 PM
RNS
Total Voting Rights
27 Dec 2013 07:13 AM
RNS
AZ and Shionogi extend Crestor agreement
19 Dec 2013 02:00 PM
RNS
Director/PDMR Shareholding
19 Dec 2013 07:50 AM
RNS
AZ to acquire BMS share of diabetes assets
17 Dec 2013 06:13 PM
RNS
STATEMENT ON ESOMEPRAZOLE STRONTIUM LAUNCH IN US
13 Dec 2013 07:14 AM
RNS
Top Line Results From Phase III Study of Lesinurad
13 Dec 2013 07:00 AM
RNS
FDA Advisory Committee Recommends Dapagliflozin
12 Dec 2013 07:00 AM
RNS
FDA Advisory Committee Votes on Metreleptin
06 Dec 2013 07:00 AM
RNS
European Commission Approves Fluenz Tetra
02 Dec 2013 03:00 PM
RNS
Blocklisting Interim Review
02 Dec 2013 01:00 PM
RNS
Total Voting Rights
22 Nov 2013 01:42 PM
RNS
XIGDUO POSITIVE CHMP OPINION FOR TYPE 2 DIABETES
19 Nov 2013 07:00 AM
RNS
NDA for Naloxegol accepted by US FDA
01 Nov 2013 04:00 PM
RNS
Total Voting Rights
01 Nov 2013 01:45 PM
RNS
Director/PDMR Shareholding
31 Oct 2013 07:02 AM
RNS
US Court Decision in Pulmicort Respules Litigation
31 Oct 2013 07:01 AM
RNS
Marc Dunoyer Appointed Chief Financial Officer
31 Oct 2013 07:00 AM
RNS
3rd Quarter Results
30 Oct 2013 09:00 AM
RNS
Notice of Results
30 Oct 2013 07:00 AM
RNS
ASTRAZENECA ADVANCES BENRALIZUMAB TO PHASE III
22 Oct 2013 07:00 AM
RNS
AstraZeneca starts phase III study for selumetinib
15 Oct 2013 07:00 AM
RNS
Medimmune acquires Spirogen
07 Oct 2013 07:00 AM
RNS
MedImmune completes Amplimmune acquisition
01 Oct 2013 04:00 PM
RNS
Total Voting Rights
30 Sep 2013 07:01 AM
RNS
MAA FOR OLAPARIB ACCEPTED BY EMA
27 Sep 2013 07:00 AM
RNS
MAA APPLICATION FOR NALOXEGOL ACCEPTED
20 Sep 2013 12:54 PM
RNS
Fluenz Tetra receives positive CHMP opinion in EU
04 Sep 2013 07:00 AM
RNS
Starts phase III clinical programme for olaparib
02 Sep 2013 03:00 PM
RNS
Total Voting Rights
27 Aug 2013 07:00 AM
RNS
MEDIMMUNE ACQUIRES AMPLIMMUNE
01 Aug 2013 04:00 PM
RNS
Total Voting Rights
01 Aug 2013 03:00 PM
RNS
Director/PDMR Shareholding
01 Aug 2013 07:00 AM
RNS
Half Yearly Pipeline Update
01 Aug 2013 07:00 AM
RNS
Half Yearly Report
31 Jul 2013 09:00 AM
RNS
Notice of Results
31 Jul 2013 07:00 AM
RNS
Collaborates with FibroGen on anaemia treatment

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings